Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients-authors’ response.

ingentiumby ingentium

In Coronavirus Literature.

Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients-authors’ response.

Publication date: Oct 07, 2024

Concepts Keywords
Antimicrob Antimicrob
Authors Authors
Immunocompromised Chemother
Suboptimal Cilgavimab
Therapy Combination
Immunocompromised
Infections
Patients
Persistent
Remdesivir
Response
Sars
Suboptimal
Therapy
Tixagevimab

Semantics

Type Source Name
disease MESH SARS-CoV-2 infections
disease MESH immunocompromised patients

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *